nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—Bromodiphenhydramine—Toremifene—breast cancer	0.0782	0.344	CrCrCtD
Fluoxetine—CYP2D6—breast cancer	0.0637	0.301	CbGaD
Fluoxetine—Orphenadrine—Toremifene—breast cancer	0.0615	0.27	CrCrCtD
Fluoxetine—CYP3A4—breast cancer	0.0546	0.258	CbGaD
Fluoxetine—Bromodiphenhydramine—Tamoxifen—breast cancer	0.0491	0.216	CrCrCtD
Fluoxetine—ALB—breast cancer	0.0476	0.225	CbGaD
Fluoxetine—ABCB1—breast cancer	0.0455	0.215	CbGaD
Fluoxetine—SIGMAR1—Raloxifene—breast cancer	0.0392	0.111	CbGbCtD
Fluoxetine—Orphenadrine—Tamoxifen—breast cancer	0.0386	0.17	CrCrCtD
Fluoxetine—SIGMAR1—Tamoxifen—breast cancer	0.0259	0.0736	CbGbCtD
Fluoxetine—CYP2B6—Thiotepa—breast cancer	0.0159	0.0451	CbGbCtD
Fluoxetine—CYP1A2—Anastrozole—breast cancer	0.0123	0.0349	CbGbCtD
Fluoxetine—CYP1A2—Toremifene—breast cancer	0.0112	0.0319	CbGbCtD
Fluoxetine—CYP2C9—Anastrozole—breast cancer	0.0111	0.0314	CbGbCtD
Fluoxetine—CYP3A5—Lapatinib—breast cancer	0.011	0.0313	CbGbCtD
Fluoxetine—CYP2B6—Raloxifene—breast cancer	0.0106	0.0301	CbGbCtD
Fluoxetine—ABCB1—Toremifene—breast cancer	0.00982	0.0279	CbGbCtD
Fluoxetine—CYP2C19—Lapatinib—breast cancer	0.00887	0.0252	CbGbCtD
Fluoxetine—CYP3A4—Exemestane—breast cancer	0.00848	0.0241	CbGbCtD
Fluoxetine—CYP2C9—Idarubicin—breast cancer	0.00838	0.0238	CbGbCtD
Fluoxetine—CYP2D6—Idarubicin—breast cancer	0.00766	0.0218	CbGbCtD
Fluoxetine—CYP3A4—Letrozole—breast cancer	0.00721	0.0205	CbGbCtD
Fluoxetine—ABCB1—Lapatinib—breast cancer	0.00716	0.0204	CbGbCtD
Fluoxetine—CYP2B6—Tamoxifen—breast cancer	0.00699	0.0199	CbGbCtD
Fluoxetine—CYP3A4—Anastrozole—breast cancer	0.00643	0.0183	CbGbCtD
Fluoxetine—CYP3A4—Toremifene—breast cancer	0.00588	0.0167	CbGbCtD
Fluoxetine—CYP3A5—Tamoxifen—breast cancer	0.00551	0.0157	CbGbCtD
Fluoxetine—CYP3A4—Fulvestrant—breast cancer	0.00547	0.0155	CbGbCtD
Fluoxetine—CYP2B6—Irinotecan—breast cancer	0.00537	0.0153	CbGbCtD
Fluoxetine—ALB—Irinotecan—breast cancer	0.00526	0.015	CbGbCtD
Fluoxetine—ALB—Fluorouracil—breast cancer	0.00505	0.0144	CbGbCtD
Fluoxetine—CYP3A4—Thiotepa—breast cancer	0.00487	0.0139	CbGbCtD
Fluoxetine—CYP2C9—Capecitabine—breast cancer	0.00459	0.0131	CbGbCtD
Fluoxetine—CYP3A4—Ixabepilone—breast cancer	0.00446	0.0127	CbGbCtD
Fluoxetine—CYP2C19—Tamoxifen—breast cancer	0.00444	0.0126	CbGbCtD
Fluoxetine—CYP3A4—Lapatinib—breast cancer	0.00429	0.0122	CbGbCtD
Fluoxetine—CYP3A5—Paclitaxel—breast cancer	0.00429	0.0122	CbGbCtD
Fluoxetine—CYP3A5—Irinotecan—breast cancer	0.00423	0.012	CbGbCtD
Fluoxetine—CYP1A2—Tamoxifen—breast cancer	0.0041	0.0117	CbGbCtD
Fluoxetine—ABCB1—Vinorelbine—breast cancer	0.00397	0.0113	CbGbCtD
Fluoxetine—CYP2D6—Vinorelbine—breast cancer	0.00374	0.0106	CbGbCtD
Fluoxetine—CYP2C9—Tamoxifen—breast cancer	0.00369	0.0105	CbGbCtD
Fluoxetine—ABCB1—Tamoxifen—breast cancer	0.00359	0.0102	CbGbCtD
Fluoxetine—ABCB1—Mitoxantrone—breast cancer	0.0035	0.00994	CbGbCtD
Fluoxetine—CYP2D6—Tamoxifen—breast cancer	0.00338	0.00961	CbGbCtD
Fluoxetine—CYP3A4—Raloxifene—breast cancer	0.00325	0.00924	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—breast cancer	0.0031	0.00881	CbGbCtD
Fluoxetine—ABCB1—Gemcitabine—breast cancer	0.00309	0.00878	CbGbCtD
Fluoxetine—CYP1A2—Fluorouracil—breast cancer	0.00302	0.00859	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—breast cancer	0.00293	0.00834	CbGbCtD
Fluoxetine—CYP2C9—Paclitaxel—breast cancer	0.00288	0.00818	CbGbCtD
Fluoxetine—ABCB1—Paclitaxel—breast cancer	0.00279	0.00794	CbGbCtD
Fluoxetine—ALB—Methotrexate—breast cancer	0.00279	0.00792	CbGbCtD
Fluoxetine—ABCB1—Irinotecan—breast cancer	0.00275	0.00783	CbGbCtD
Fluoxetine—CYP2C9—Fluorouracil—breast cancer	0.00272	0.00774	CbGbCtD
Fluoxetine—ABCB1—Vinblastine—breast cancer	0.00245	0.00696	CbGbCtD
Fluoxetine—CYP3A4—Vinorelbine—breast cancer	0.00238	0.00677	CbGbCtD
Fluoxetine—CYP2D6—Vinblastine—breast cancer	0.00231	0.00656	CbGbCtD
Fluoxetine—CYP3A4—Tamoxifen—breast cancer	0.00215	0.00611	CbGbCtD
Fluoxetine—CYP3A4—Mitoxantrone—breast cancer	0.0021	0.00596	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—breast cancer	0.00202	0.00574	CbGbCtD
Fluoxetine—CYP3A4—Paclitaxel—breast cancer	0.00167	0.00475	CbGbCtD
Fluoxetine—CYP3A4—Irinotecan—breast cancer	0.00165	0.00469	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—breast cancer	0.0015	0.00428	CbGbCtD
Fluoxetine—CYP3A4—Vinblastine—breast cancer	0.00147	0.00417	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—breast cancer	0.00146	0.00414	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—breast cancer	0.00142	0.00403	CbGbCtD
Fluoxetine—CYP3A4—Docetaxel—breast cancer	0.00121	0.00344	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—breast cancer	0.000901	0.00256	CbGbCtD
Fluoxetine—ALB—mammary gland—breast cancer	0.000407	0.052	CbGeAlD
Fluoxetine—SIGMAR1—mammary gland—breast cancer	0.000393	0.0502	CbGeAlD
Fluoxetine—SIGMAR1—nipple—breast cancer	0.000325	0.0415	CbGeAlD
Fluoxetine—CYP2C9—mammary gland—breast cancer	0.000254	0.0325	CbGeAlD
Fluoxetine—ORM1—endometrium—breast cancer	0.000232	0.0296	CbGeAlD
Fluoxetine—CYP1A2—nipple—breast cancer	0.000221	0.0283	CbGeAlD
Fluoxetine—SIGMAR1—endometrium—breast cancer	0.000196	0.0251	CbGeAlD
Fluoxetine—ORM1—female reproductive system—breast cancer	0.000192	0.0245	CbGeAlD
Fluoxetine—ORM1—bone marrow—breast cancer	0.000181	0.0232	CbGeAlD
Fluoxetine—SIGMAR1—uterus—breast cancer	0.000181	0.0231	CbGeAlD
Fluoxetine—SIGMAR1—pituitary gland—breast cancer	0.000177	0.0227	CbGeAlD
Fluoxetine—SIGMAR1—adipose tissue—breast cancer	0.000177	0.0226	CbGeAlD
Fluoxetine—HTR2C—female reproductive system—breast cancer	0.000173	0.0221	CbGeAlD
Fluoxetine—ALB—adrenal gland—breast cancer	0.000164	0.021	CbGeAlD
Fluoxetine—SLC6A4—female reproductive system—breast cancer	0.000164	0.0209	CbGeAlD
Fluoxetine—ORM1—endocrine gland—breast cancer	0.000162	0.0208	CbGeAlD
Fluoxetine—SIGMAR1—adrenal gland—breast cancer	0.000159	0.0203	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—breast cancer	0.000153	0.0196	CbGeAlD
Fluoxetine—SIGMAR1—female gonad—breast cancer	0.000148	0.0189	CbGeAlD
Fluoxetine—SLC6A2—female reproductive system—breast cancer	0.000144	0.0184	CbGeAlD
Fluoxetine—HTR2A—embryo—breast cancer	0.000143	0.0183	CbGeAlD
Fluoxetine—SLC6A2—adrenal gland—breast cancer	0.000141	0.018	CbGeAlD
Fluoxetine—SLC6A4—endocrine gland—breast cancer	0.000138	0.0177	CbGeAlD
Fluoxetine—CYP2B6—skin of body—breast cancer	0.000136	0.0174	CbGeAlD
Fluoxetine—Orphenadrine—SCN10A—breast cancer	0.000136	0.217	CrCbGaD
Fluoxetine—Cinacalcet—CYP2D6—breast cancer	0.000133	0.213	CrCbGaD
Fluoxetine—SLC6A2—endocrine gland—breast cancer	0.000122	0.0156	CbGeAlD
Fluoxetine—HTR2A—epithelium—breast cancer	0.000117	0.0149	CbGeAlD
Fluoxetine—CYP3A5—adipose tissue—breast cancer	0.000116	0.0149	CbGeAlD
Fluoxetine—CYP2C19—endocrine gland—breast cancer	0.000115	0.0147	CbGeAlD
Fluoxetine—Cinacalcet—CYP3A4—breast cancer	0.000114	0.183	CrCbGaD
Fluoxetine—ORM1—lymph node—breast cancer	0.000112	0.0144	CbGeAlD
Fluoxetine—CYP2B6—female reproductive system—breast cancer	0.000106	0.0136	CbGeAlD
Fluoxetine—CYP2C9—female reproductive system—breast cancer	0.000105	0.0134	CbGeAlD
Fluoxetine—Duloxetine—CYP2D6—breast cancer	0.000104	0.167	CrCbGaD
Fluoxetine—CYP2B6—adrenal gland—breast cancer	0.000104	0.0132	CbGeAlD
Fluoxetine—ALB—lymph node—breast cancer	9.85e-05	0.0126	CbGeAlD
Fluoxetine—CYP3A5—female gonad—breast cancer	9.72e-05	0.0124	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—breast cancer	9.5e-05	0.0121	CbGeAlD
Fluoxetine—HTR2A—pituitary gland—breast cancer	9.46e-05	0.0121	CbGeAlD
Fluoxetine—CYP1A2—endocrine gland—breast cancer	9.37e-05	0.012	CbGeAlD
Fluoxetine—ABCB1—embryo—breast cancer	9.36e-05	0.012	CbGeAlD
Fluoxetine—CYP3A5—endocrine gland—breast cancer	9.04e-05	0.0116	CbGeAlD
Fluoxetine—CYP2B6—endocrine gland—breast cancer	8.98e-05	0.0115	CbGeAlD
Fluoxetine—CYP2C9—endocrine gland—breast cancer	8.89e-05	0.0114	CbGeAlD
Fluoxetine—HTR2A—female reproductive system—breast cancer	8.66e-05	0.0111	CbGeAlD
Fluoxetine—HTR2A—adrenal gland—breast cancer	8.45e-05	0.0108	CbGeAlD
Fluoxetine—SLC6A2—lymph node—breast cancer	8.43e-05	0.0108	CbGeAlD
Fluoxetine—CYP3A4—female reproductive system—breast cancer	8.01e-05	0.0102	CbGeAlD
Fluoxetine—CYP2D6—female reproductive system—breast cancer	7.89e-05	0.0101	CbGeAlD
Fluoxetine—ABCB1—epithelium—breast cancer	7.64e-05	0.00976	CbGeAlD
Fluoxetine—HTR2A—endocrine gland—breast cancer	7.33e-05	0.00936	CbGeAlD
Fluoxetine—CYP2D6—female gonad—breast cancer	7.18e-05	0.00917	CbGeAlD
Fluoxetine—ABCB1—endometrium—breast cancer	6.85e-05	0.00875	CbGeAlD
Fluoxetine—CYP3A4—endocrine gland—breast cancer	6.78e-05	0.00867	CbGeAlD
Fluoxetine—CYP2D6—endocrine gland—breast cancer	6.67e-05	0.00853	CbGeAlD
Fluoxetine—ABCB1—uterus—breast cancer	6.31e-05	0.00807	CbGeAlD
Fluoxetine—ABCB1—pituitary gland—breast cancer	6.2e-05	0.00792	CbGeAlD
Fluoxetine—ABCB1—adipose tissue—breast cancer	6.17e-05	0.00789	CbGeAlD
Fluoxetine—ABCB1—female reproductive system—breast cancer	5.67e-05	0.00725	CbGeAlD
Fluoxetine—ABCB1—adrenal gland—breast cancer	5.54e-05	0.00708	CbGeAlD
Fluoxetine—Atomoxetine—CYP2D6—breast cancer	5.45e-05	0.0875	CrCbGaD
Fluoxetine—ABCB1—bone marrow—breast cancer	5.36e-05	0.00685	CbGeAlD
Fluoxetine—ABCB1—female gonad—breast cancer	5.16e-05	0.0066	CbGeAlD
Fluoxetine—ABCB1—endocrine gland—breast cancer	4.8e-05	0.00614	CbGeAlD
Fluoxetine—Atomoxetine—CYP3A4—breast cancer	4.68e-05	0.075	CrCbGaD
Fluoxetine—Orphenadrine—CYP3A4—breast cancer	3.57e-05	0.0573	CrCbGaD
Fluoxetine—ABCB1—lymph node—breast cancer	3.32e-05	0.00424	CbGeAlD
Fluoxetine—Vomiting—Fluorouracil—breast cancer	1.21e-05	8.24e-05	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—breast cancer	1.21e-05	8.24e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—breast cancer	1.21e-05	8.24e-05	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—breast cancer	1.21e-05	8.22e-05	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—breast cancer	1.21e-05	8.22e-05	CcSEcCtD
Fluoxetine—Insomnia—Capecitabine—breast cancer	1.2e-05	8.19e-05	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—breast cancer	1.2e-05	8.18e-05	CcSEcCtD
Fluoxetine—Rash—Fluorouracil—breast cancer	1.2e-05	8.17e-05	CcSEcCtD
Fluoxetine—Dermatitis—Fluorouracil—breast cancer	1.2e-05	8.17e-05	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—breast cancer	1.2e-05	8.16e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Capecitabine—breast cancer	1.2e-05	8.13e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—breast cancer	1.2e-05	8.13e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Paclitaxel—breast cancer	1.2e-05	8.13e-05	CcSEcCtD
Fluoxetine—Headache—Fluorouracil—breast cancer	1.19e-05	8.12e-05	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—breast cancer	1.19e-05	8.1e-05	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—breast cancer	1.19e-05	8.09e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—breast cancer	1.19e-05	8.08e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Capecitabine—breast cancer	1.19e-05	8.08e-05	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—breast cancer	1.19e-05	8.07e-05	CcSEcCtD
Fluoxetine—Nausea—Mitoxantrone—breast cancer	1.18e-05	8.04e-05	CcSEcCtD
Fluoxetine—Nausea—Irinotecan—breast cancer	1.18e-05	8.04e-05	CcSEcCtD
Fluoxetine—Pain—Docetaxel—breast cancer	1.18e-05	8e-05	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—breast cancer	1.18e-05	8e-05	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—breast cancer	1.18e-05	7.99e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Capecitabine—breast cancer	1.17e-05	7.97e-05	CcSEcCtD
Fluoxetine—Chills—Epirubicin—breast cancer	1.17e-05	7.97e-05	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—breast cancer	1.17e-05	7.93e-05	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—breast cancer	1.16e-05	7.92e-05	CcSEcCtD
Fluoxetine—Asthenia—Paclitaxel—breast cancer	1.16e-05	7.92e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Capecitabine—breast cancer	1.16e-05	7.87e-05	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—breast cancer	1.15e-05	7.85e-05	CcSEcCtD
Fluoxetine—Nausea—Gemcitabine—breast cancer	1.15e-05	7.83e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Capecitabine—breast cancer	1.15e-05	7.82e-05	CcSEcCtD
Fluoxetine—Fatigue—Capecitabine—breast cancer	1.15e-05	7.81e-05	CcSEcCtD
Fluoxetine—Pruritus—Paclitaxel—breast cancer	1.15e-05	7.81e-05	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—breast cancer	1.14e-05	7.78e-05	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—breast cancer	1.14e-05	7.77e-05	CcSEcCtD
Fluoxetine—Constipation—Capecitabine—breast cancer	1.14e-05	7.75e-05	CcSEcCtD
Fluoxetine—Pain—Capecitabine—breast cancer	1.14e-05	7.75e-05	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—breast cancer	1.14e-05	7.73e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—breast cancer	1.13e-05	7.71e-05	CcSEcCtD
Fluoxetine—Nausea—Fluorouracil—breast cancer	1.13e-05	7.7e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—breast cancer	1.13e-05	7.67e-05	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—breast cancer	1.13e-05	7.66e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—breast cancer	1.12e-05	7.65e-05	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—breast cancer	1.12e-05	7.64e-05	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—breast cancer	1.12e-05	7.62e-05	CcSEcCtD
Fluoxetine—Tension—Epirubicin—breast cancer	1.12e-05	7.59e-05	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—breast cancer	1.11e-05	7.57e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Paclitaxel—breast cancer	1.11e-05	7.55e-05	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—breast cancer	1.1e-05	7.51e-05	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—breast cancer	1.1e-05	7.48e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Capecitabine—breast cancer	1.1e-05	7.46e-05	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—breast cancer	1.1e-05	7.45e-05	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—breast cancer	1.09e-05	7.43e-05	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—breast cancer	1.09e-05	7.42e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Capecitabine—breast cancer	1.09e-05	7.41e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—breast cancer	1.09e-05	7.4e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—breast cancer	1.09e-05	7.4e-05	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—breast cancer	1.09e-05	7.4e-05	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—breast cancer	1.08e-05	7.37e-05	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—breast cancer	1.08e-05	7.34e-05	CcSEcCtD
Fluoxetine—Dizziness—Paclitaxel—breast cancer	1.07e-05	7.3e-05	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—breast cancer	1.07e-05	7.26e-05	CcSEcCtD
Fluoxetine—Cough—Methotrexate—breast cancer	1.06e-05	7.21e-05	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—breast cancer	1.06e-05	7.2e-05	CcSEcCtD
Fluoxetine—Urticaria—Capecitabine—breast cancer	1.06e-05	7.2e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—breast cancer	1.05e-05	7.17e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Capecitabine—breast cancer	1.05e-05	7.16e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Capecitabine—breast cancer	1.05e-05	7.16e-05	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—breast cancer	1.05e-05	7.16e-05	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—breast cancer	1.05e-05	7.15e-05	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—breast cancer	1.05e-05	7.15e-05	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—breast cancer	1.04e-05	7.11e-05	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—breast cancer	1.04e-05	7.05e-05	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—breast cancer	1.03e-05	7.03e-05	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—breast cancer	1.03e-05	7.03e-05	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—breast cancer	1.03e-05	7.03e-05	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—breast cancer	1.03e-05	7.02e-05	CcSEcCtD
Fluoxetine—Vomiting—Paclitaxel—breast cancer	1.03e-05	7.02e-05	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—breast cancer	1.03e-05	7.01e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.03e-05	6.99e-05	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—breast cancer	1.03e-05	6.97e-05	CcSEcCtD
Fluoxetine—Rash—Paclitaxel—breast cancer	1.02e-05	6.96e-05	CcSEcCtD
Fluoxetine—Dermatitis—Paclitaxel—breast cancer	1.02e-05	6.95e-05	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—breast cancer	1.02e-05	6.95e-05	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—breast cancer	1.02e-05	6.95e-05	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—breast cancer	1.02e-05	6.95e-05	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—breast cancer	1.02e-05	6.93e-05	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—breast cancer	1.02e-05	6.92e-05	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—breast cancer	1.02e-05	6.92e-05	CcSEcCtD
Fluoxetine—Headache—Paclitaxel—breast cancer	1.02e-05	6.91e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—breast cancer	1.01e-05	6.89e-05	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—breast cancer	1.01e-05	6.88e-05	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—breast cancer	1e-05	6.83e-05	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—breast cancer	1e-05	6.8e-05	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—breast cancer	9.99e-06	6.8e-05	CcSEcCtD
Fluoxetine—Cough—Epirubicin—breast cancer	9.92e-06	6.75e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—breast cancer	9.91e-06	6.74e-05	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—breast cancer	9.87e-06	6.71e-05	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—breast cancer	9.85e-06	6.7e-05	CcSEcCtD
Fluoxetine—Infection—Methotrexate—breast cancer	9.85e-06	6.7e-05	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—breast cancer	9.81e-06	6.68e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Capecitabine—breast cancer	9.81e-06	6.67e-05	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—breast cancer	9.76e-06	6.64e-05	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—breast cancer	9.73e-06	6.62e-05	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—breast cancer	9.72e-06	6.61e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—breast cancer	9.71e-06	6.6e-05	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—breast cancer	9.68e-06	6.58e-05	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—breast cancer	9.68e-06	6.58e-05	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—breast cancer	9.68e-06	6.58e-05	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—breast cancer	9.67e-06	6.57e-05	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—breast cancer	9.64e-06	6.56e-05	CcSEcCtD
Fluoxetine—Nausea—Paclitaxel—breast cancer	9.64e-06	6.56e-05	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—breast cancer	9.63e-06	6.55e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	9.61e-06	6.54e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—breast cancer	9.58e-06	6.52e-05	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—breast cancer	9.56e-06	6.5e-05	CcSEcCtD
Fluoxetine—Asthenia—Capecitabine—breast cancer	9.56e-06	6.5e-05	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—breast cancer	9.49e-06	6.45e-05	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—breast cancer	9.47e-06	6.44e-05	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—breast cancer	9.45e-06	6.43e-05	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—breast cancer	9.45e-06	6.43e-05	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—breast cancer	9.43e-06	6.42e-05	CcSEcCtD
Fluoxetine—Pruritus—Capecitabine—breast cancer	9.42e-06	6.41e-05	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—breast cancer	9.42e-06	6.4e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—breast cancer	9.41e-06	6.4e-05	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—breast cancer	9.35e-06	6.36e-05	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—breast cancer	9.3e-06	6.32e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—breast cancer	9.28e-06	6.31e-05	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—breast cancer	9.26e-06	6.3e-05	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—breast cancer	9.24e-06	6.29e-05	CcSEcCtD
Fluoxetine—Infection—Epirubicin—breast cancer	9.22e-06	6.27e-05	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—breast cancer	9.18e-06	6.24e-05	CcSEcCtD
Fluoxetine—Shock—Epirubicin—breast cancer	9.13e-06	6.21e-05	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—breast cancer	9.11e-06	6.2e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Capecitabine—breast cancer	9.11e-06	6.2e-05	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—breast cancer	9.1e-06	6.19e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—breast cancer	9.08e-06	6.18e-05	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—breast cancer	9.08e-06	6.18e-05	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—breast cancer	9.05e-06	6.16e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—breast cancer	9.03e-06	6.14e-05	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—breast cancer	9.01e-06	6.13e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—breast cancer	8.97e-06	6.1e-05	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—breast cancer	8.97e-06	6.1e-05	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—breast cancer	8.96e-06	6.09e-05	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—breast cancer	8.96e-06	6.09e-05	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—breast cancer	8.96e-06	6.09e-05	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—breast cancer	8.92e-06	6.07e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—breast cancer	8.9e-06	6.06e-05	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	8.89e-06	6.05e-05	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—breast cancer	8.85e-06	6.02e-05	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—breast cancer	8.84e-06	6.02e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—breast cancer	8.84e-06	6.01e-05	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—breast cancer	8.81e-06	5.99e-05	CcSEcCtD
Fluoxetine—Dizziness—Capecitabine—breast cancer	8.81e-06	5.99e-05	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—breast cancer	8.76e-06	5.96e-05	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—breast cancer	8.75e-06	5.95e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—breast cancer	8.73e-06	5.94e-05	CcSEcCtD
Fluoxetine—Rash—Docetaxel—breast cancer	8.67e-06	5.9e-05	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—breast cancer	8.67e-06	5.9e-05	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—breast cancer	8.66e-06	5.89e-05	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—breast cancer	8.66e-06	5.89e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—breast cancer	8.62e-06	5.86e-05	CcSEcCtD
Fluoxetine—Headache—Docetaxel—breast cancer	8.62e-06	5.86e-05	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—breast cancer	8.58e-06	5.84e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—breast cancer	8.56e-06	5.82e-05	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—breast cancer	8.55e-06	5.81e-05	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—breast cancer	8.53e-06	5.8e-05	CcSEcCtD
Fluoxetine—Pain—Methotrexate—breast cancer	8.48e-06	5.77e-05	CcSEcCtD
Fluoxetine—Vomiting—Capecitabine—breast cancer	8.47e-06	5.76e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—breast cancer	8.45e-06	5.75e-05	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—breast cancer	8.45e-06	5.74e-05	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—breast cancer	8.41e-06	5.72e-05	CcSEcCtD
Fluoxetine—Rash—Capecitabine—breast cancer	8.4e-06	5.71e-05	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—breast cancer	8.39e-06	5.71e-05	CcSEcCtD
Fluoxetine—Dermatitis—Capecitabine—breast cancer	8.39e-06	5.71e-05	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—breast cancer	8.38e-06	5.7e-05	CcSEcCtD
Fluoxetine—Headache—Capecitabine—breast cancer	8.34e-06	5.67e-05	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—breast cancer	8.34e-06	5.67e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—breast cancer	8.33e-06	5.67e-05	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—breast cancer	8.3e-06	5.64e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—breast cancer	8.27e-06	5.63e-05	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—breast cancer	8.25e-06	5.61e-05	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—breast cancer	8.18e-06	5.57e-05	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—breast cancer	8.17e-06	5.56e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—breast cancer	8.17e-06	5.56e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—breast cancer	8.17e-06	5.55e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—breast cancer	8.11e-06	5.51e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—breast cancer	8.07e-06	5.49e-05	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—breast cancer	8.02e-06	5.46e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—breast cancer	8.01e-06	5.45e-05	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—breast cancer	8e-06	5.44e-05	CcSEcCtD
Fluoxetine—Pain—Epirubicin—breast cancer	7.93e-06	5.4e-05	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—breast cancer	7.93e-06	5.4e-05	CcSEcCtD
Fluoxetine—Nausea—Capecitabine—breast cancer	7.91e-06	5.38e-05	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—breast cancer	7.88e-06	5.36e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—breast cancer	7.84e-06	5.33e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—breast cancer	7.84e-06	5.33e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.82e-06	5.32e-05	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—breast cancer	7.76e-06	5.28e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—breast cancer	7.71e-06	5.24e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—breast cancer	7.65e-06	5.21e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—breast cancer	7.65e-06	5.2e-05	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—breast cancer	7.63e-06	5.19e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—breast cancer	7.59e-06	5.16e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—breast cancer	7.56e-06	5.14e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—breast cancer	7.46e-06	5.08e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—breast cancer	7.41e-06	5.04e-05	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—breast cancer	7.4e-06	5.03e-05	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—breast cancer	7.37e-06	5.01e-05	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—breast cancer	7.34e-06	4.99e-05	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—breast cancer	7.34e-06	4.99e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—breast cancer	7.33e-06	4.99e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—breast cancer	7.33e-06	4.99e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—breast cancer	7.3e-06	4.97e-05	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—breast cancer	7.11e-06	4.84e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—breast cancer	7.07e-06	4.81e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—breast cancer	7.02e-06	4.77e-05	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—breast cancer	7.01e-06	4.77e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—breast cancer	6.84e-06	4.65e-05	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—breast cancer	6.82e-06	4.64e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—breast cancer	6.79e-06	4.62e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—breast cancer	6.79e-06	4.62e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—breast cancer	6.78e-06	4.61e-05	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—breast cancer	6.66e-06	4.53e-05	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—breast cancer	6.56e-06	4.46e-05	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—breast cancer	6.56e-06	4.46e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—breast cancer	6.35e-06	4.32e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—breast cancer	6.32e-06	4.3e-05	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—breast cancer	6.3e-06	4.29e-05	CcSEcCtD
Fluoxetine—Rash—Methotrexate—breast cancer	6.25e-06	4.25e-05	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—breast cancer	6.25e-06	4.25e-05	CcSEcCtD
Fluoxetine—Headache—Methotrexate—breast cancer	6.21e-06	4.22e-05	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—breast cancer	6.16e-06	4.19e-05	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—breast cancer	6.14e-06	4.17e-05	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—breast cancer	6.07e-06	4.13e-05	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—breast cancer	5.9e-06	4.01e-05	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—breast cancer	5.89e-06	4.01e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—breast cancer	5.87e-06	4e-05	CcSEcCtD
Fluoxetine—Rash—Epirubicin—breast cancer	5.85e-06	3.98e-05	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—breast cancer	5.84e-06	3.98e-05	CcSEcCtD
Fluoxetine—Headache—Epirubicin—breast cancer	5.81e-06	3.95e-05	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—breast cancer	5.68e-06	3.86e-05	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—breast cancer	5.51e-06	3.75e-05	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—breast cancer	5.46e-06	3.71e-05	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—breast cancer	5.41e-06	3.68e-05	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—breast cancer	5.41e-06	3.68e-05	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—breast cancer	5.38e-06	3.66e-05	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—breast cancer	5.1e-06	3.47e-05	CcSEcCtD
Fluoxetine—CYP2C19—Metabolism—GPX1—breast cancer	1.69e-06	3.13e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.69e-06	3.13e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—breast cancer	1.69e-06	3.12e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—breast cancer	1.68e-06	3.12e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGF—breast cancer	1.68e-06	3.11e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—breast cancer	1.67e-06	3.1e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—breast cancer	1.67e-06	3.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ACHE—breast cancer	1.67e-06	3.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—breast cancer	1.67e-06	3.09e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ERCC2—breast cancer	1.66e-06	3.07e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—breast cancer	1.66e-06	3.07e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GPX1—breast cancer	1.65e-06	3.06e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—breast cancer	1.64e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NCOA1—breast cancer	1.64e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—breast cancer	1.63e-06	3.03e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—breast cancer	1.63e-06	3.02e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—breast cancer	1.63e-06	3.02e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—breast cancer	1.63e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOS3—breast cancer	1.63e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.62e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NCOR1—breast cancer	1.62e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—breast cancer	1.62e-06	3.01e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ERCC2—breast cancer	1.62e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—STK11—breast cancer	1.62e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP19A1—breast cancer	1.62e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—breast cancer	1.61e-06	2.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PLA2G4A—breast cancer	1.61e-06	2.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NCOR1—breast cancer	1.61e-06	2.98e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAV1—breast cancer	1.6e-06	2.97e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—breast cancer	1.6e-06	2.96e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP17A1—breast cancer	1.58e-06	2.92e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS1—breast cancer	1.56e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO1—breast cancer	1.56e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—breast cancer	1.56e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1—breast cancer	1.56e-06	2.88e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—breast cancer	1.56e-06	2.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT2—breast cancer	1.56e-06	2.88e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GPX1—breast cancer	1.55e-06	2.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—breast cancer	1.55e-06	2.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—breast cancer	1.55e-06	2.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—breast cancer	1.54e-06	2.86e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GPX1—breast cancer	1.54e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—breast cancer	1.54e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAF1—breast cancer	1.54e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.53e-06	2.84e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2D6—breast cancer	1.53e-06	2.84e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RELA—breast cancer	1.53e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ERCC2—breast cancer	1.53e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—breast cancer	1.53e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—breast cancer	1.52e-06	2.82e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—breast cancer	1.52e-06	2.82e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—breast cancer	1.52e-06	2.82e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.52e-06	2.81e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ERCC2—breast cancer	1.51e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—breast cancer	1.51e-06	2.79e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—COMT—breast cancer	1.5e-06	2.79e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOA2—breast cancer	1.5e-06	2.78e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—breast cancer	1.5e-06	2.78e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—breast cancer	1.5e-06	2.78e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—breast cancer	1.5e-06	2.77e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—breast cancer	1.49e-06	2.77e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—breast cancer	1.49e-06	2.76e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	1.48e-06	2.74e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SERPINE1—breast cancer	1.48e-06	2.74e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—breast cancer	1.48e-06	2.73e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ITPR1—breast cancer	1.47e-06	2.73e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—breast cancer	1.47e-06	2.73e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—breast cancer	1.46e-06	2.71e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—breast cancer	1.46e-06	2.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FASN—breast cancer	1.46e-06	2.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BCHE—breast cancer	1.45e-06	2.69e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—breast cancer	1.44e-06	2.67e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NOS3—breast cancer	1.44e-06	2.67e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAV1—breast cancer	1.44e-06	2.67e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—breast cancer	1.43e-06	2.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A5—breast cancer	1.43e-06	2.66e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—breast cancer	1.43e-06	2.65e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—breast cancer	1.42e-06	2.63e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—breast cancer	1.42e-06	2.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOS3—breast cancer	1.41e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—breast cancer	1.41e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NOS3—breast cancer	1.41e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAV1—breast cancer	1.4e-06	2.6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—breast cancer	1.39e-06	2.58e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—breast cancer	1.39e-06	2.58e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NQO1—breast cancer	1.39e-06	2.57e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC2A1—breast cancer	1.39e-06	2.57e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—breast cancer	1.38e-06	2.56e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—breast cancer	1.38e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.38e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—breast cancer	1.38e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NCOR1—breast cancer	1.38e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.37e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—breast cancer	1.37e-06	2.55e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—breast cancer	1.37e-06	2.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	1.34e-06	2.49e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—breast cancer	1.34e-06	2.49e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—breast cancer	1.34e-06	2.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—breast cancer	1.34e-06	2.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAF1—breast cancer	1.33e-06	2.47e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—breast cancer	1.33e-06	2.46e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—breast cancer	1.33e-06	2.46e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RELA—breast cancer	1.33e-06	2.46e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1B1—breast cancer	1.33e-06	2.46e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAV1—breast cancer	1.32e-06	2.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—breast cancer	1.32e-06	2.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPX1—breast cancer	1.32e-06	2.44e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—breast cancer	1.32e-06	2.44e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAV1—breast cancer	1.31e-06	2.43e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—breast cancer	1.31e-06	2.43e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—breast cancer	1.3e-06	2.42e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—breast cancer	1.3e-06	2.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—breast cancer	1.3e-06	2.4e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ERCC2—breast cancer	1.29e-06	2.4e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—breast cancer	1.29e-06	2.38e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—breast cancer	1.28e-06	2.38e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—breast cancer	1.28e-06	2.37e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK8—breast cancer	1.27e-06	2.35e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOA1—breast cancer	1.27e-06	2.35e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—breast cancer	1.26e-06	2.34e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.25e-06	2.32e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—breast cancer	1.25e-06	2.32e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—STK11—breast cancer	1.25e-06	2.31e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP19A1—breast cancer	1.25e-06	2.31e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—breast cancer	1.24e-06	2.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—breast cancer	1.22e-06	2.26e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—breast cancer	1.22e-06	2.25e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NOS3—breast cancer	1.21e-06	2.24e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—breast cancer	1.21e-06	2.24e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—breast cancer	1.21e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SRC—breast cancer	1.2e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—breast cancer	1.2e-06	2.22e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—breast cancer	1.2e-06	2.22e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—breast cancer	1.2e-06	2.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—breast cancer	1.19e-06	2.21e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—breast cancer	1.17e-06	2.17e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—breast cancer	1.17e-06	2.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—breast cancer	1.16e-06	2.16e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—COMT—breast cancer	1.16e-06	2.15e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—breast cancer	1.16e-06	2.15e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	1.16e-06	2.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—breast cancer	1.16e-06	2.14e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—breast cancer	1.15e-06	2.13e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—breast cancer	1.15e-06	2.13e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—breast cancer	1.14e-06	2.11e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—breast cancer	1.14e-06	2.11e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ITPR1—breast cancer	1.14e-06	2.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—breast cancer	1.13e-06	2.1e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	1.13e-06	2.09e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—breast cancer	1.13e-06	2.09e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—breast cancer	1.12e-06	2.08e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—breast cancer	1.12e-06	2.08e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAV1—breast cancer	1.12e-06	2.08e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—breast cancer	1.12e-06	2.07e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—breast cancer	1.11e-06	2.06e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—breast cancer	1.11e-06	2.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—breast cancer	1.11e-06	2.05e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK8—breast cancer	1.1e-06	2.04e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.1e-06	2.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—breast cancer	1.09e-06	2.03e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NOS3—breast cancer	1.09e-06	2.02e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—breast cancer	1.08e-06	2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—breast cancer	1.07e-06	1.99e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—breast cancer	1.07e-06	1.99e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.07e-06	1.98e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NOS3—breast cancer	1.06e-06	1.97e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOR1—breast cancer	1.06e-06	1.97e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—breast cancer	1.06e-06	1.97e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.06e-06	1.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—breast cancer	1.06e-06	1.96e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—breast cancer	1.05e-06	1.95e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—breast cancer	1.05e-06	1.95e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—breast cancer	1.05e-06	1.94e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SRC—breast cancer	1.04e-06	1.93e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—breast cancer	1.04e-06	1.92e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—breast cancer	1.02e-06	1.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.02e-06	1.88e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPX1—breast cancer	1.02e-06	1.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—breast cancer	1.01e-06	1.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—breast cancer	1.01e-06	1.86e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—breast cancer	1e-06	1.86e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NOS3—breast cancer	1e-06	1.85e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ERCC2—breast cancer	9.98e-07	1.85e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—breast cancer	9.96e-07	1.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—breast cancer	9.95e-07	1.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NOS3—breast cancer	9.92e-07	1.84e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—breast cancer	9.8e-07	1.82e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—breast cancer	9.71e-07	1.8e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—breast cancer	9.67e-07	1.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—breast cancer	9.62e-07	1.78e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—breast cancer	9.38e-07	1.74e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—breast cancer	9.36e-07	1.73e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—breast cancer	9.33e-07	1.73e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—breast cancer	9.24e-07	1.71e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—breast cancer	9.16e-07	1.7e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—breast cancer	9.15e-07	1.7e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—breast cancer	9.15e-07	1.7e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	9.15e-07	1.69e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—breast cancer	9.07e-07	1.68e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—breast cancer	8.98e-07	1.66e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—breast cancer	8.86e-07	1.64e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—breast cancer	8.85e-07	1.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—breast cancer	8.68e-07	1.61e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAV1—breast cancer	8.65e-07	1.6e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—breast cancer	8.65e-07	1.6e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NOS3—breast cancer	8.48e-07	1.57e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—breast cancer	8.47e-07	1.57e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—breast cancer	8.46e-07	1.57e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—breast cancer	8.1e-07	1.5e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—breast cancer	8.1e-07	1.5e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—breast cancer	7.98e-07	1.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	7.94e-07	1.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—breast cancer	7.92e-07	1.47e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—breast cancer	7.91e-07	1.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—breast cancer	7.88e-07	1.46e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—breast cancer	7.83e-07	1.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—breast cancer	7.75e-07	1.44e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—breast cancer	7.68e-07	1.42e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—breast cancer	7.47e-07	1.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—breast cancer	7.35e-07	1.36e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—breast cancer	7.03e-07	1.3e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—breast cancer	6.93e-07	1.28e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—breast cancer	6.84e-07	1.27e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—breast cancer	6.82e-07	1.26e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—breast cancer	6.76e-07	1.25e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—breast cancer	6.62e-07	1.23e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NOS3—breast cancer	6.54e-07	1.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—breast cancer	6.49e-07	1.2e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—breast cancer	6.47e-07	1.2e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—breast cancer	6.12e-07	1.13e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—breast cancer	6.04e-07	1.12e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—breast cancer	5.98e-07	1.11e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—breast cancer	5.98e-07	1.11e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—breast cancer	5.63e-07	1.04e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—breast cancer	5.58e-07	1.03e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—breast cancer	5.57e-07	1.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—breast cancer	5.22e-07	9.67e-06	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—breast cancer	5e-07	9.26e-06	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—breast cancer	4.88e-07	9.04e-06	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—breast cancer	4.77e-07	8.84e-06	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—breast cancer	4.6e-07	8.52e-06	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—breast cancer	4.56e-07	8.45e-06	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—breast cancer	3.9e-07	7.22e-06	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—breast cancer	3.68e-07	6.82e-06	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—breast cancer	3.01e-07	5.57e-06	CbGpPWpGaD
